Sphingolipids, including the two central bioactive lipids ceramide and sphingosine-1-
phosphate (S1P), have opposing roles in regulating cancer cell death and survival …

In higher eukaryotes, fine-tuned activation of protein-coding genes and many non-coding
RNAs pivots around the regulated activity of RNA polymerase II (Pol II). The Integrator …

Protein phosphatases act as key regulators of multiple important cellular processes and are
attractive therapeutic targets for various diseases. Although extensive effort has been …

Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …

Tumor relapse and metastasis are the primary causes of poor survival rates in patients with
advanced cancer despite successful resection or chemotherapeutic treatment. A primary …

Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-
ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self …

Chronic myeloid leukemia (CML) is caused by BCRABL1 in a cell with the biological
potential, intrinsic or acquired, to cause leukemia. This cell is commonly termed the CML …

Chronic myeloid leukaemia (CML) arises after transformation of a haemopoietic stem cell
(HSC) by the protein-tyrosine kinase BCR–ABL. Direct inhibition of BCR–ABL kinase has …

Chronic myeloid leukaemia (CML) is a myeloproliferative disorder arising in the
haemopoietic stem cell (HSC) compartment. This disease is characterised by a reciprocal t …

Every year, more than 8000 new cases of chronic myeloid leukemia (CML) are diagnosed in
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …